These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29333117)

  • 1. Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence.
    Matsui Y; Horikawa M; Jahangiri Noudeh Y; Kaufman JA; Kolbeck KJ; Farsad K
    Radiol Oncol; 2017 Dec; 51(4):393-400. PubMed ID: 29333117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis.
    Park C; Gwon DI; Chu HH; Kim JW; Kim JH; Ko GY
    Abdom Radiol (NY); 2021 Aug; 46(8):3729-3737. PubMed ID: 33141259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma.
    Wang H; Han Y; Chen G; Jin L
    Quant Imaging Med Surg; 2023 Jul; 13(7):4077-4088. PubMed ID: 37456312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and potential utility of non-enhanced computed tomography performed immediately after transarterial chemoembolization for hepatocellular carcinoma.
    Kim MY; Heo S; Choi S; Suh CH; Lee ES; Park HJ; Kim KW
    J Gastrointest Oncol; 2024 Jun; 15(3):1141-1152. PubMed ID: 38989419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
    Chen CS; Li FK; Guo CY; Xiao JC; Hu HT; Cheng HT; Zheng L; Zong DW; Ma JL; Jiang L; Li HL
    Oncotarget; 2016 Feb; 7(6):7241-52. PubMed ID: 26769845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
    Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
    Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC).
    Yamada R; Bassaco B; Bracewell S; Gillen K; Kocher M; Collins H; Anderson MB; Guimaraes M
    J Gastrointest Oncol; 2019 Apr; 10(2):348-353. PubMed ID: 31032104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
    El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
    Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cone-Beam Computed Tomography Correlates with Conventional Helical Computed Tomography in Evaluation of Lipiodol Accumulation in HCC after Chemoembolization.
    Ishikawa T; Abe S; Hoshii A; Yamada Y; Iiduka A; Nemoto T; Takeda K; Yoshida T
    PLoS One; 2016; 11(1):e0145546. PubMed ID: 26752696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.
    de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization.
    Kim JW; Lee CH; Park YS; Seo TS; Song MG; Kim JH; Kim KA; Park CM
    Eur J Radiol; 2017 Apr; 89():169-176. PubMed ID: 28267535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).
    Ma W; Jia J; Wang S; Bai W; Yi J; Bai M; Quan Z; Yin Z; Fan D; Wang J; Han G
    Theranostics; 2014; 4(7):736-44. PubMed ID: 24883123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome.
    Herber S; Biesterfeld S; Franz U; Schneider J; Thies J; Schuchmann M; Düber C; Pitton MB; Otto G
    Cardiovasc Intervent Radiol; 2008; 31(4):768-77. PubMed ID: 18196335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
    Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ
    BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.
    Cho SM; Chu HH; Kim JW; Kim JH; Gwon DI
    Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33919658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
    World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
    Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
    Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.